{"filings":[{"id":96223,"accession_number":"0001850902-26-000007","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01","5.05"],"status":"ready","headline":"Teknova Q1 revenue $11.1M (+13% YoY); reaffirms FY 2026 guidance $42-44M","event_type":"earnings","confidence":"high","bullets":["Total revenue $11.1M, up 13% YoY; Clinical Solutions revenue surged 85% to $2.1M.","Net loss $4.6M (diluted EPS -$0.08) vs $4.6M; Adjusted EBITDA improved to -$2.0M from -$2.5M.","Gross margin expanded to 34.2% from 30.7%; Free Cash Outflow improved to $3.6M from $4.3M.","Reaffirmed FY 2026 revenue guidance $42-44M and Free Cash Outflow under $10M.","Cash and short-term investments $17.8M; total borrowings $13.2M at quarter end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":11077000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109924,"accession_number":"0001193125-26-076592","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Alpha Teknova reports Q4 and FY2025 revenue growth, provides 2026 guidance of $42-44M","event_type":"earnings","confidence":"high","bullets":["Full year 2025 total revenue $40.5M, up 7% from $37.7M in 2024.","Q4 2025 revenue $10.0M, up 8% from $9.3M in Q4 2024.","Clinical Solutions revenue up 47% in Q4 to $2.7M; 25% annual growth in Clinical Solutions customers.","Net loss improved to $17.3M in 2025 from $26.7M in 2024; Adjusted EBITDA improved to -$6.7M from -$14.5M.","Company expects 2026 revenue of $42-44M and free cash outflow less than $10M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":40520000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126504,"accession_number":"0001193125-25-269488","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q3 revenue $10.5M (+9% YoY); net loss narrows to $4.3M; reaffirms FY2025 guidance","event_type":"earnings","confidence":"high","bullets":["Revenue $10.5M, up 9% from Q3 2024; Lab Essentials $8.3M (+16%), Clinical Solutions $1.7M (-13%).","Gross margin 30.7% vs 0.9% (Q3 2024); prior year included $2.8M non-recurring inventory charges.","Net loss $4.3M ($0.08/share) vs $7.6M ($0.15/share) a year ago; Adjusted EBITDA -$1.6M vs -$5.0M.","Free Cash Outflow $2.4M, flat YoY. Cash & short-term investments $22.1M; borrowings $13.2M.","Reaffirms FY2025 revenue guidance $39-42M and Free Cash Outflow <$12M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":30536000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143250,"accession_number":"0000950170-25-105005","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q2 revenue $10.3M (+7% YoY); net loss narrows to $3.6M; reaffirms FY25 guidance $39-42M","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue of $10.3M, up 7% from $9.6M in Q2 2024.","Net loss of $3.6M ($0.07 per share) vs $5.4M ($0.13) in prior-year quarter.","Gross margin improved to 38.7% from 29.2% on manufacturing efficiency gains.","Adjusted EBITDA loss narrowed to $0.8M from $2.6M; free cash outflow $2.3M vs $3.0M.","Company reaffirms 2025 revenue guidance of $39-42M and free cash outflow <$12M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":20082000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161380,"accession_number":"0000950170-25-089004","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Alpha Teknova shareholders elect Demski and Herzick as Class I directors; auditor ratified","event_type":"other_material","confidence":"high","bullets":["Martha J. Demski elected with 42,901,743 votes for (99.1% of votes cast, excluding broker non-votes).","Alexander Herzick elected with 42,594,414 votes for (98.3% of votes cast, excluding broker non-votes).","Ratification of Grant Thornton LLP as auditor for FY 2025 passed with 47,336,767 for, 6,200 against, 13,554 abstentions.","88.62% of outstanding shares (47,356,521) represented at the June 17, 2025 annual meeting.","Approximately 4.0 million broker non-votes did not affect the director election outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161379,"accession_number":"0000950170-25-067005","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teknova Q1 revenue up 5% to $9.8M, net loss narrows to $4.6M, guidance reaffirmed","event_type":"earnings","confidence":"high","bullets":["Q1 total revenue $9.8M (+5% YoY); Lab Essentials $8.1M (+12%), Clinical Solutions $1.2M (-32%).","Net loss narrowed to $4.6M ($0.09/share) from $8.1M ($0.20/share) in Q1 2024.","Adjusted EBITDA loss improved to $2.5M from $3.8M; free cash outflow decreased to $4.3M from $6.7M.","Exclusive collaboration with Pluristyx to manufacture/distribute PluriFreeze cryopreservation system in US/Canada.","Reaffirms FY2025 revenue guidance of $39-42M and free cash outflow under $12M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":9795000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179548,"accession_number":"0000950170-25-031995","cik":1850902,"company_name":"Alpha Teknova, Inc.","ticker":"TKNO","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Teknova reports FY2024 revenue $37.7M (+3% YoY), guides FY2025 $39-42M, amends credit facility","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue $37.7M (+3% YoY); Q4 revenue $9.3M (+18% YoY). Clinical Solutions Q4 revenue $1.85M (+110% YoY).","Net loss FY2024 $26.7M ($0.57/share) vs $36.8M ($1.16) in FY2023; adjusted EBITDA -$14.5M vs -$19.8M.","2025 guidance: revenue $39-42M, free cash outflow <$12M (vs -$13.5M in FY2024).","New $28.245M credit facility ($23.245M term + $5M revolver), maturity March 2030, principal pay starting April 2028.","Covenants: minimum net revenue $39M for TTM ending Dec 2025; minimum cash $8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}